InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 273246

Friday, 09/23/2016 9:23:59 PM

Friday, September 23, 2016 9:23:59 PM

Post# of 345969
CP, I think this is what led up to Dr Spigels advancement to CSO at Sara Cannon Research Institute

I think if all read this below....and realize Dr Spigel would not be promoted to CSO for no reason....along with Dr Spigel having AZ disclosures in 2015...hmmmm ....yes, this makes perfect sense now with Dr Spigel as lead author on Sunrise biomarker data coming ...


2013 SCRI teams with AZ for biomarkers
https://www.genomeweb.com/clinical-genomics/sarah-cannon-inks-personalized-medicine-pact-astrazeneca

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News